Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07712484 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care

Study acronym: COCCIMETRICS
StatusNot Yet Recruiting
PhasePhase 2
SponsorF2G Ltd
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from F2G Ltd

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Eligibility criteria expanded, about 19 words
    • Study title expanded, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
F2G Ltd
2 trials monitored
See 1 trial at risk
The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).
Trial Details
NCT Number NCT07712484
Lead Sponsor F2G Ltd
Collaborators: IQVIA RDS Inc.
Conditions
(from sponsor)		 Coccidioidomycosis, Disseminated Fungal Infection, Coccidioides Infection, Coccidioides Immitis Infection, Coccidioides Posadasii Infection, Coccidioidomycosis Infection, San Joaquin Valley Fever, Valley Fever
Related terms Coccidioidomycosis, Invasive Fungal Infections, Mycoses
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov